Atala Financial Inc Sells 100 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Atala Financial Inc trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,935 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Atala Financial Inc’s holdings in Gilead Sciences were worth $217,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the business. Redwood Financial Network Corp boosted its holdings in Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 98 shares in the last quarter. Nicolet Advisory Services LLC lifted its holdings in shares of Gilead Sciences by 2.9% in the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 100 shares during the period. Peak Financial Advisors LLC boosted its stake in shares of Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock valued at $677,000 after buying an additional 100 shares in the last quarter. Perkins Coie Trust Co grew its holdings in Gilead Sciences by 2.6% during the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 100 shares during the period. Finally, Investment Research & Advisory Group Inc. raised its position in Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 100 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer now owns 620,268 shares of the company’s stock, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the sale, the insider now directly owns 120,168 shares in the company, valued at approximately $13,238,908.56. This represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,500 shares of company stock worth $5,236,245 in the last quarter. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Bank of America lifted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Oppenheimer dropped their target price on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, April 25th. Finally, Morgan Stanley increased their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Stock Down 1.2%

GILD stock opened at $105.93 on Thursday. The company has a market cap of $131.77 billion, a price-to-earnings ratio of 22.30, a P/E/G ratio of 0.69 and a beta of 0.29. Gilead Sciences, Inc. has a twelve month low of $66.01 and a twelve month high of $119.96. The business has a 50 day moving average price of $106.21 and a two-hundred day moving average price of $103.03. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The business’s revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.32) earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.98%. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.